Table 1.
Summary of the included studies
| Author(s) | Year | Type of study | Targeted therapy | Types of cancers eligible | Total recruited | No. of mucinous ovarian carcinoma | No. of mucinous ovarian carcinoma patients per study arm | Overall study outcomes |
| Gore et al5 | 2019 | Phase III | Bevacizumab | Stage II - IV or recurrent mucinous ovarian carcinoma. | 50 | 18* | Bevacizumab - 24 No bevacizumab −26 |
Trial terminated due to poor accrual. |
| Burger et al8 | 2011 | Phase III | Bevacizumab | Stage III/IV epithelial ovarian, primary peritoneal, or fallopian-tube cancer. | 1873 | 19 | Bevacizumab initiation - 5 Bevacizumab through - 8 No bevacizumab - 6 |
Progression-free survival (PFS) improved by 4 months with bevacizumab/chemotherapy compared with chemotherapy alone. |
| Perren et al9 | 2011 | Phase III | Bevacizumab | Stage IIB -IV epithelial ovarian, primary peritoneal, or fallopian-tube cancer. | 1528 | 15 | Bevacizumab – 19 No bevacizumab – 15 |
Improved PFS by 2 months in the chemotherapy and bevacizumab treatment group. |
| Aghajanian et al10 | 2012 | Phase III (OCEANS) | Bevacizumab | Recurrent ovarian, fallopian tube or primary peritoneal cancer. | 484 | 4 | Bevacizumab – 3 No bevacizumab – 1 |
Improved PFS in chemotherapy/ bevacizumab compared with chemotherapy alone. |
| Coleman et al11 | 2017 | Phase III | Bevacizumab | Recurrent ovarian, fallopian tube or primary peritoneal cancer. | 674 | 4 | Bevacizumab - 2 No bevacizumab - 2 |
Improved overall survival (OS) by 5 months in the chemotherapy and bevacizumab group. |
| Winer et al12 | 2010 | Case report | Bevacizumab | – | – | 1 | – | Stable disease for 9 months before disease recurrence. Achieved stable disease again after reinitiating bevacizumab. |
| Tarumi et al13 | 2017 | Case report | Bevacizumab | – | – | 1 | – | Responded with stable disease and improved ECOG performance status. |
| Ledermann et al14 | 2016 | Phase III (ICON6) | Cediranib | Recurrent ovarian, fallopian tube or primary peritoneal cancer. | 456 | 4 | Maintenance - 1 Concurrent - 3 No cediranib - 0 |
Improved PFS – 11.0 months for maintenance cediranib vs 8.7 months for chemotherapy /no maintenance therapy. |
| Baumann et al15 | 2012 | Phase II | Sunitinib | Epithelial ovarian, primary peritoneal or fallopian tube cancer. | 73 | 3 | Non-continuous sunitinib - 1 Continuous sunitinib - 2 |
Higher response rate for non-continuous sunitinib. No significant difference observed in PFS or OS between the two arms (continuous and non-continuous therapy). |
| du Bois et al16 Ray-Coquard et al17 | 2016, 2019 | Phase III (AGO-OVAR12) | Nintedanib | Stage IIB–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. | 1366 | 37 | Nintedanib - 25 No Nintedanib - 12 |
Significant improvement in PFS. No improvement in median OS – placebo better than nintedanib in patients with mucinous ovarian carcinoma. |
| Vergote et al18 | 2019 | Phase III (AGO-OVAR16) | Pazopanib | Stage II–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. | 940 | 40 | Pazopanib - 24 No pazopanib −16 |
Prolonged PFS – 17.9 months for pazopanib vs 12.3 months for placebo. No improvement in median OS. |
| Richardson et al19 | 2018 | Phase II | Pazopanib | Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. | 106 | 1 | Pazopanib - 1 No pazopanib - 0 |
No improvement in PFS or OS. |
| McAlpine et al20 | 2009 | Case report | Trastuzumab | – | – | 2 | – | Both achieved stable disease. Disease recurred when therapy ceased. One patient improved with re-initiation of trastuzumab. |
| Jain et al21 | 2012 | Case report | Trastuzumab | – | – | 1 | – | Downtrend in the serum marker CEA and improved ECOG performance status. |
| Benjamin et al22 | 2014 | Case report | Trastuzumab | – | – | 1 | – | Progressive disease. |
| Vergote et al25 | 2014 | Phase III | Erlotinib | Stage II - IV epithelial ovarian, primary peritoneal, or fallopian tube cancer. | 835 | 14 | Erlotinib – 6 No erlotinib – 8 |
No improvement in PFS or OS. |
| Leijen et al27 | 2016 | Phase II | AZD1775 | Recurrent epithelial ovarian cancer (with TP53 mutation). | 23 | 2 | No randomized arms | One mucinous ovarian carcinoma patient achieved partial response and the other patient had progressive disease. |
| Sabbatini et al28 | 2013 | Phase III | Abagovomab | Stage III - IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. | 888 | 9 | Abagovomab – 6 No abagovomab – 3 |
No improvement in PFS or OS observed. |
| Schilder et al31 | 2012 | Phase II | Dasatinib | Epithelial ovarian, primary peritoneal cancer. | 34 | 1 | No randomized arms | No improvement in PFS. |
| Meier et al33 | 2012 | Phase II | Lonafarnib | Stage IIB - IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. | 105 | 5 | Lonafarnib – 1 No lonafarnib – 4 |
No improvement in PFS or OS. |
*50 patients recruited initially, only 18 confirmed to have mucinous ovarian carcinoma.